Literature DB >> 99031

Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.

K Chatterjee, B Massie, S Rubin, H Gelberg, B H Brundage, T A Ports.   

Abstract

Increased left ventricular filling pressure and reduced cardiac output are two major hemodynamic deficits in pump failure. In patients with chronic heart failure, consequences of these hemodynamic deficits and diminished cardiac reserve are manifested initially during stress and eventually at rest. The purpose of therapeutic interventions include reduction of ventricular filling pressure increase in cardiac output and improvement in cardiac reserve. To achieve these goals, the hemodynamic effects of predominantly venodilators (nitrates), predominantly arteriolar dilators (hydralazine) and the combination of nitrates and hydralazine were evaluated in patients with chronic heart failure at rest: left ventricular filling pressure (mm Hg) control 28, nitrates 17, hydralazine 25, nitrates plus hydralazine 18; cardiac output (liters/min/m2) control 2.1, nitrates 2.1, hydralazine 3.2, nitrates plus hydralazine 3.3; mean blood pressure (mm Hg) control 87, nitrates 85, hydralazine 83, nitrates plus hydralazine 85. These data suggest improved left ventricular performance with a combination of nitrates and hydralazine. Exercise hemodynamics improved in some patients, suggesting that such vasodilator therapy may be beneficial in chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 99031     DOI: 10.1016/0002-9343(78)90702-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.

Authors:  J N Cohn
Journal:  Drugs       Date:  1994       Impact factor: 9.546

2.  Long-term treatment of congestive heart failure with captopril.

Authors:  M Komajda; M Eugene; J Evans; G Drobinski; J L Laurenceau; Y Grosgogeat
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

3.  Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.

Authors:  E G Breen; D Mulhall; J A Keogh
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Dynamics of the light reflex and the influence of age on the human pupil measured by television pupillometry [proceedings].

Authors:  P R Bourne; S A Smith; S E Smith
Journal:  J Physiol       Date:  1979-08       Impact factor: 5.182

5.  Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.

Authors:  H Drexler; H Löllgen; H Just
Journal:  Klin Wochenschr       Date:  1981-06-15

Review 6.  Vasodilator therapy in chronic congestive heart failure.

Authors:  A B Schwartz; K Chatterjee
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

7.  Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction.

Authors:  D J Fitzgerald; W G O'Callaghan; K O'Malley; J Horgan; E O'Brien
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 8.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

9.  Abnormal haemodynamic postural response in patients with chronic heart failure.

Authors:  Anne-Sophie G T Bronzwaer; Lysander W J Bogert; Berend E Westerhof; Jan J Piek; Mat J A P Daemen; Johannes J van Lieshout
Journal:  ESC Heart Fail       Date:  2017-02-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.